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Abstract. 
 
OCI-5/GPC3 is a member of the glypican 
family. Glypicans are heparan sulfate proteoglycans 
that are bound to the cell surface through a glycosyl-
phosphatidylinositol anchor. It has recently been shown 
that the 
 
OCI-5/GPC3
 
 gene is mutated in patients with 
the Simpson-Golabi-Behmel Syndrome (SGBS), an 
X-linked disorder characterized by pre- and postnatal 
overgrowth and various visceral and skeletal dysmor-
phisms. Some of these dysmorphisms could be the re-
sult of deficient growth inhibition or apoptosis in cer-
tain cell types during development. Here we present 
evidence indicating that OCI-5/GPC3 induces apopto-
sis in cell lines derived from mesothelioma (II14) and 
breast cancer (MCF-7). This induction, however, is cell 
line specific since it is not observed in NIH 3T3 fibro-
blasts or HT-29 colorectal tumor cells. We also show 
that the apoptosis-inducing activity in II14 and MCF-7 
cells requires the anchoring of OCI-5/GPC3 to the cell 
membrane. The glycosaminoglycan chains, on the other 
hand, are not required. MCF-7 cells can be rescued 
from OCI-5/GPC3–induced cell death by insulin-like 
growth factor 2. This factor has been implicated in 
Beckwith-Wiedemann, an overgrowth syndrome that 
has many similarities with SGBS. The discovery that 
OCI-5/GPC3 is able to induce apoptosis in a cell line–
specific manner provides an insight into the mechanism 
that, at least in part, is responsible for the phenotype of 
SGBS patients.
 
T
 
he
 
 Simpson-Golabi-Behmel Syndrome (SGBS)
 
1
 
 is
an X-linked condition characterized by pre- and
postnatal overgrowth (Garganta and Bodurtha,
1992; Gurrieri et al., 1992; Terespolsky et al., 1995). Af-
fected individuals have several dysmorphisms that can in-
clude a distinct facial appearance, macroglossia, cleft palate,
cardiac defects, enlarged and dysplastic kidneys, cryptor-
chidism, hypospadia, hernias, supernumerary nipples, verte-
bral and rib anomalies, coccygeal bony appendage, syn-
dactyly, and polydactyly (Garganta and Bodurtha, 1992;
Gurrieri et al., 1992; Terespolsky et al., 1995). In addition,
these patients have an increased risk for the development
of Wilms’ tumors (Hughes-Benzie et al., 1992). Premature
death is also very frequent (Garganta and Bodurtha, 1992).
Recently, Pilia et al. (1996) reported that individuals
with SGBS display mutations in the OCI-5/glypican 3
(
 
OCI-5/GPC3
 
) gene. OCI-5/GPC3 is a member of the
glypican family. Glypicans are heparan sulfate proteogly-
cans that are bound to the cell surface through a glycosyl-
phosphatidylinositol (GPI) anchor (David, 1993). Five
members of the glypican family have been identified in
mammals: GPC1 (glypican) (David et al., 1990), GPC2
(cerebroglycan) (Stipp et al., 1994), GPC3 (OCI-5) (Fil-
mus et al., 1995), GPC4 (K-glypican) (Watanabe et al.,
1995), and GPC5 (Saunders et al., 1997; Veugelers et al.,
1997). Although the degree of similarity between the dif-
ferent glypicans varies from 20 to 50%, the positions of the
13 cysteines and the putative glycosaminoglycan attach-
ment sites are well conserved across the family (Veugelers
et al., 1997). Recently, the cloning of 
 
dally
 
, a 
 
Drosophila
 
gene with significant homology to the glypican family, was
reported (Nakato et al., 1995). This gene also shares the
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structural features common to the vertebrate glypicans.
Regulatory mutations of 
 
dally
 
 have a severe impact on the
postembryonic development of the nervous system and
produce morphological defects in several tissues, including
the eyes, antennae, wings, and genitalia (Nakato et al.,
1995).
The specific functions of glypicans are still not known,
but experimental evidence has been provided indicating
that (
 
a
 
) GPC1 can act in vitro as a co-receptor for “hep-
arin binding” growth factors such as basic fibroblast
growth factor (Steinfeld et al., 1996); and (
 
b
 
) 
 
dally
 
 controls
cellular responses to Decapentaplegic, a transforming
growth factor 
 
b
 
–related morphogen (Jackson et al., 1997).
 
OCI-5
 
, the rat homologue of 
 
GPC3
 
, was originally iden-
tified as a gene that is developmentally regulated in the
intestine (Filmus et al., 1988). OCI-5 is expressed at high
levels in numerous tissues during development but is
downregulated in most adult tissues (Filmus, J., unpub-
lished observations). Functional studies on OCI-5/GPC3
have not yet been reported, but the phenotype of the SGBS
patients suggests that this gene is involved in the control of
cell proliferation and/or survival. For example, syndactyly
in SGBS patients may be the consequence of deficient in-
duction of growth inhibition or apoptosis in the mesenchy-
mal cells forming the interdigital and interphalangeal spaces
during development (Jacobson et al., 1997).
Here we present experimental evidence indicating that
OCI-5/GPC3 can induce apoptosis and that this apoptosis-
inducing capacity of OCI-5/GPC3 is cell line specific.
 
Materials and Methods
 
Cell Lines
 
The asbestos-induced rat mesothelioma cell line II14 and the rat mesothe-
lial cell line NRM2 were kindly provided by Dr. C. Walker (M.D. Ander-
son, Smithville, TX). They were cultured in Ham’s F-12: DME (1:1;
GIBCO BRL, Gaithersburg, MD) with 10% heat-inactivated FBS and
supplemented with 0.1 
 
m
 
g/ml hydrocortisone, 2.5 
 
m
 
g/ml insulin, 2.5 
 
m
 
g/ml
transferrin, and 2.5 ng/ml sodium selenite. COS-1, NIH 3T3, MCF-7, HT-
29, and HepG2 cell lines (American Type Culture Collection, Rockville,
MD) were cultured in DME supplemented with 10% FBS. All cell lines
were maintained at 37
 
8
 
C in a humidified atmosphere with 5% CO
 
2
 
.
 
Generation of OCI-5/GPC3 Mutants
 
To delete the GPI-anchoring domain, an AgeI site was introduced by
changing bases 1765 and 1766 from TC to GG (Filmus et al., 1988) using a
PCR-based site-directed mutagenesis method (Cadwell and Joyce, 1995).
After mutation, the AgeI-EcoRI fragment containing the 3
 
9
 
 end of the
OCI-5 cDNA was removed and replaced by a linker sequence (5
 
9
 
-CCG-
GAGCTGACTAACTGAATT-3
 
9
 
) that contains three stop codons.
To mutate the two potential glycosaminoglycan (GAG) attachment
sites, serine residues 494 and 508 (Filmus et al., 1988) were mutated to ala-
nine by site-directed mutagenesis (Cadwell and Joyce, 1995). Mutations
were verified by DNA sequencing.
 
Transfections
 
For the colony forming efficiency assay, the wild-type or mutated hemag-
glutinin A (HA)-tagged OCI-5/GPC3 cDNA (Filmus et al., 1995) was in-
troduced into the pEF-BOS vector (Mizushima and Nagata, 1990) and
transfected into cells by using Lipofectin according to the manufacturer’s
instructions (GIBCO BRL). Cell cultures were then selected in the pres-
ence of 600 
 
m
 
g/ml of geneticin, and surviving colonies were counted 2 wk
later. Experiments were performed in triplicate and repeated using differ-
ent batches of DNA. In some cases, individual colonies were isolated us-
ing cloning cylinders and expanded in the presence of 200 
 
m
 
g/ml of geneticin.
To generate MCF-7 cells with Cd
 
2
 
1
 
-inducible OCI-5/GPC3 expression,
the cDNA was cloned into a vector under the control of the rat metal-
lothionein promoter (Filmus et al., 1994), and transfection was performed
with Lipofectin. Selection was performed in the presence of 600 
 
m
 
g/ml ge-
neticin. Surviving clones were isolated and expanded. To induce expres-
sion, MCF-7 cells were incubated with 5 
 
m
 
M CdCl
 
2 
 
in serum-containing
medium.
Transient transfection assays of MCF-7 cells were performed as previ-
ously described (Muzio et al., 1996). Briefly, cells were transfected with a
 
b
 
-galactosidase expression vector and a fivefold excess of the pEF-BOS
vector or a vector containing wild-type or mutant OCI-5/GPC3. Serum
was removed 12 h after transfection, and 36 h later cells were either fixed
and stained with X-gal or lysed to prepare cytoplasmic extracts to be used
in the Cell Death Elisa Assay. In addition, cells transfected in parallel
plates were lysed, and the expression of OCI-5/GPC3 was assessed by
Western blot of immunoprecipitated extracts as described below.
Transient transfection and [
 
35
 
S]sulfate labeling of COS-1 cells was per-
formed as previously described (Filmus et al., 1995).
 
Characterization of OCI-5/GPC3 Protein in 
Transfected Clones
 
OCI-5/GPC3 expression was investigated by Western blotting. When indi-
cated, OCI-5/GPC3 was immunoprecipitated before the Western blotting.
Briefly, cells were lysed in RIPA buffer containing protease inhibitors
(2 mM PMSF, 10 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupeptin, 1 
 
m
 
g/ml pepstatin,
and 10 mM EDTA). Conditioned media was concentrated using Centri-
con-10 filters (Amicon, Beverley, MA). Lysates and conditioned media
were immunoprecipitated using the anti-HA monoclonal antibody 12CA5
(20 
 
m
 
g/ml) and protein A beads. Immunoprecipitates were rinsed three
times with RIPA buffer, and an equal volume of 2
 
3
 
 reducing sample
buffer was added. After boiling for 5 min, proteins were run on a 4–9%
polyacrylamide gradient gel or a 7.5% polyacrylamide gel. For Western
blotting, proteins were transferred to a polyvinyl difluoride membrane
(Dupont, Boston, MA). Membranes were blocked in PBS plus 5% nonfat
dry milk for 1 h at room temperature and then incubated for 1 h with 1 
 
m
 
g/
ml 12CA5 antibody. After incubation with horseradish peroxidase anti–
mouse or anti–rabbit secondary antibody for 1 h, the bands were detected
using ECL reagents (Amersham Corp., Arlington Heights, IL). The gel
containing [
 
35
 
S]sulfate-labeled proteins immunoprecipitated with the
12CA5 antibody was analyzed by autoradiography.
 
Analysis of Poly ADP Ribose Polymerase
 
Cells were washed with PBS, collected by scraping, and lysed with RIPA
buffer containing protease inhibitors. Proteins were then transferred to a
polyvinyl difluoride membrane and subjected to Western blotting as de-
scribed above, using 2 
 
m
 
g of an anti–poly ADP ribose polymerase (PARP)
antibody (Boehringer-Mannheim Corp., Indianapolis, IN).
 
Apoptosis Assays in the Mesothelioma Cell Line II14
 
2 
 
3 
 
10
 
5
 
 cells were seeded in 3.5-cm plates in complete medium. After 24 h,
cells were rinsed once with PBS, once with serum-free medium (1:1 F12/
DME), and incubated in the same medium for 48 h. Floating and attached
cells were then counted using a hemocytometer.
 
Quantitation of Apoptosis by the Cell Death Elisa Assay
 
This assay was performed using the Cell Death Elisa kit from Boehringer-
Mannheim following the manufacturer’s instructions. Briefly, microwells
were coated with the antihistone antibody, and cytoplasmic extract from
5 
 
3 
 
10
 
3
 
 cells was added to each well. Binding of histone-DNA conjugates
to the histone antibody was detected with an anti-DNA antibody conju-
gated to peroxidase.
 
Generation of Polyclonal Antibodies
against OCI-5/GPC3
 
The polyclonal antibody against human GPC3 was generated by injecting
sheep with a glutathione-S-transferase fusion protein containing the last
70 amino acids of GPC3. The polyclonal antibody was affinity purified
against the immunogen. The rat polyclonal antibody against rat OCI-5
was generated by injecting rabbits with a glutathione-S-transferase fusion 
Gonzalez et al. 
 
Glypican-3 Induces Apoptosis in a Cell Line–specific Manner
 
1409
 
protein containing the last 70 amino acids of OCI-5. The polyclonal anti-
body was affinity purified against the immunogen.
 
Results
 
Effect of OCI-5/GPC3 Expression on Colony
Forming Efficiency
 
The fact that SGBS patients display supernumerary nip-
ples strongly suggests that OCI-5/GPC3 is involved in the
regulation of cell survival in the mammary gland during
development (Hughes-Benzie et al., 1996). We have hy-
pothesized that OCI-5/GPC3 could also be a negative reg-
ulator of survival of mammary tumor cells, which, like
mammary cells during development, are actively prolifer-
ating. To test this hypothesis we decided to transfect this
glypican into the OCI-5/GPC3–negative MCF-7 breast
cancer line. We also included in our transfection studies a
rat mesothelioma cell line (II14), since OCI-5/GPC3 is
highly expressed in normal mesothelial cells, but it is
downregulated in mesotheliomas (Testa, J.R., unpublished
observations).
In an initial attempt to investigate whether OCI-5/GPC3
has growth-suppressive activity, a colony forming effi-
ciency assay was performed. This assay has been previ-
ously used to demonstrate, for example, the growth-sup-
pressive activities of p53 and p16 (Baker et al., 1990; Lin
et al., 1996). Thus, the MCF-7 breast cancer cell line and
the II14 mesothelioma cell line were transfected with an
expression vector with or without the OCI-5/GPC3 cDNA,
and the number of colonies that grew in the presence of
geneticin were counted after 14 d of selection. Table I
shows that the number of colonies generated after OCI-5/
GPC3 transfection was reduced by 60 and 70% in II14 and
MCF-7 cells, respectively, compared with transfection with
vector control. Similar results were obtained by using at
least two different batches of DNA. To test whether this
inhibitory effect of OCI-5/GPC3 on colony forming effi-
ciency is cell line specific, we used the same expression
vectors to transfect NIH 3T3 mouse fibroblasts and the
colorectal tumor cell line HT-29 (both cell lines are OCI-5/
GPC3 negative). Table I shows that OCI-5/GPC3 did not
affect the colony forming efficiency of NIH 3T3 and HT-29
cells, since the number of colonies that grew after OCI-5/
GPC3 transfection was similar to the number obtained af-
ter transfection of the vector control.
Colonies that grew after OCI-5/GPC3 transfection were
expanded and screened for OCI-5/GPC3 expression. Only 3
out of 60 II14-derived clones and 3 out of 50 MCF-7–derived
clones displayed detectable OCI-5/GPC3. In the case of
NIH 3T3 cells and HT-29 cells, on the other hand, 90% of
the colonies were OCI-5/GPC3 positive. This confirms the
cell-specific nature of the effect of OCI-5/GPC3 in the col-
ony forming assay.
 
Transient Expression of OCI-5/GPC3 in MCF-7 Cells
 
As shown previously in colony forming assays with p53
and p16 (Baker et al., 1990; Lin et al., 1996), the inhibitory
effect of OCI-5/GPC3 in colony formation could be due to
an apoptotic-inducing activity or to an ability to inhibit cell
proliferation. To distinguish between these two possibili-
ties, the apoptotic-inducing activity of OCI-5/GPC3 was
evaluated by transient expression in MCF-7 cells. This
type of assay has been extensively used in MCF-7 cells to
identify molecules that are able to induce apoptosis (Chin-
naiyan et al., 1995; Muzio et al., 1996) and is based on the
observation that MCF-7 cells undergoing apoptosis ac-
quire a characteristic rounded morphology before detach-
ing from the dish. To identify cells that have taken up the
transfected DNA, a 
 
b
 
-galactosidase expression vector is
included in the transfection mixture. When MCF-7 cells
were transfected with the OCI-5/GPC3 expression vector,
 
.
 
80% of blue cells displayed the typical apoptotic mor-
phology. After transfection of vector control, on the other
hand, only 30% of blue cells became rounded (Fig. 1 
 
A
 
).
This experiment was repeated several times with similar
results. We have also quantitated the apoptotic-inducing
activity of OCI-5/GPC3 by using the Cell Death Elisa As-
say, which measures the amount of cytoplasmic histone-
associated DNA fragments. Fig. 1 
 
B
 
 shows that this assay
also demonstrates that OCI-5/GPC3 induces apoptosis of
MCF-7 cells after transient transfection. To verify that
OCI-5/GPC3 is being expressed in the transiently trans-
fected MCF-7 cells, a Western blot was performed. Fig. 2
shows that indeed this is the case. These results indicate,
therefore, that OCI-5/GPC3 has the capacity to induce apop-
tosis in MCF-7 cells upon transient expression.
 
Effect of Inducible Expression of OCI-5/GPC3 in
MCF-7 Cells
 
To confirm the apoptosis-inducing activity of OCI-5/
GPC3 in MCF-7 cells, we generated a clone expressing
OCI-5/GPC3 in an inducible manner. Thus, MCF-7 cells
were transfected with a vector in which the expression of
OCI-5/GPC3 was driven by the metallothionein promoter.
More than 30 clones resistant to geneticin were screened,
and three of them displayed inducible expression of OCI-5/
GPC3. Fig. 3 shows that significant levels of OCI-5/GPC3
are induced in one of these clones (MT3) after incubation
with 5 
 
m
 
M Cd
 
2
 
1
 
 overnight, although low levels of expres-
sion are also observed in uninduced cells. If the induction
is maintained for 3 d in serum-containing medium, MT3
cells start to round up and detach from the plate. Fig. 4 
 
d
 
shows that after 4 d of incubation with Cd
 
2
 
1
 
, a significant
number of MT3 cells are floating in the medium. This has
also been observed with the other two inducible clones
(data not shown). Similar treatment of parental MCF-7
cells, on the other hand, does not affect their viability (Fig.
4 
 
b
 
). To verify that OCI-5/GPC3–expressing MT3 cells are
undergoing apoptosis, the status of PARP was investi-
gated by Western blot. Fig. 3 shows that after induction of
OCI-5/GPC3 expression for 4 d, MT3 cells display the typ-
ical pattern of apoptotic cells with regard to the cleavage
 
Table I. Colony Forming Efficiency Assay
 
II14 MCF-7 NIH3T3 HT-29
 
Vector alone 100* 100 100 100
OCI-5/GPC3 41.7 
 
6
 
 2.7 29.5 
 
6
 
 3.9 92.1 
 
6
 
 11.9 104.9 
 
6
 
 1.6
 
D
 
OCI-5/GPC3 91.5 
 
6
 
 3.3 91.5 
 
6
 
 6.0 nd nd
OCI-5/GPC3 (
 
D
 
GAG) 37.4 
 
6
 
 4.3 79.4 
 
6
 
 1.7 nd nd
 
*Results are presented as percentage (mean 
 
6
 
 standard error) with respect to number
of geneticin-surviving colonies in cells transfected with vector alone. Similar results
were obtained with at least two batches of DNA. 
 
nd
 
, not done. 
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of PARP. No cleavage is observed in the parental MCF-7
cells treated with 5 
 
m
 
M Cd
 
2
 
1
 
 for the same amount of time.
We also confirmed that inducible expression of OCI-5/
GPC3 triggers apoptosis in MCF-7 cells by performing a
Cell Death Elisa Assay after 4 d of induction (Fig. 5).
 
Effect of OCI-5/GPC3 Expression on II14 
Mesothelioma Cells
 
It proved difficult to transfect II14 cells with high enough
efficiency for transient expression assays. In addition, we
have not yet been able to generate II14 mesothelioma
clones with inducible OCI-5/GPC3. However, we have ex-
panded the few clones that survived after the transfection
of constitutive OCI-5/GPC3. Fig. 6 shows a Western blot
analysis of OCI-5/GPC3 expression in three of them. This
Western blot had to be overexposed to be able to detect
the smear corresponding to the glycanated form of OCI-5/
GPC3. Still, it is obvious that in these cells there is strong
expression of the nonglycanated form of OCI-5/GPC3.
However, this is not an artifact caused by exogenous ex-
pression of OCI-5/GPC3 in II14 mesothelioma cells; when
Western blot analysis was performed on NRM2 normal
mesothelial cells and HepG2 hepatoma cells using poly-
clonal antibodies against OCI-5/GPC3, a similar strong ex-
pression of the nonglycanated form was observed (Fig. 7).
When the OCI-5/GPC3–containing mesothelioma clones
were subconfluent, no obvious indication of apoptosis was
observed. However, we noticed that when these three
clones become confluent, there is an increase in the num-
ber of cells that detach from the plate, compared with II14
parental cells or clones transfected with vector control. We
decided, therefore, to grow OCI-5/GPC3–positive and
–negative II14 clones in the absence of serum to determine
whether in this apoptosis-prone condition, a difference be-
Figure 1. Transient expression assay in MCF-7
cells. MCF-7 cells were transiently trans-
fected with RSV b-galactosidase and a five-
fold excess of (a) vector control, (b) OCI-5/
GPC3, (c) DOCI-5/GPC3, and (d) OCI-5/
GPC3D (GAG). (A) 48 h after transfection,
cells were fixed and stained with X-gal. Every
vector was transfected into triplicate plates.
The results (mean 6 standard error) were ex-
pressed as percentage of rounded (apoptotic)
cells among the blue-stained cells. The exper-
iment was repeated three times with similar
results. (B) 48 h after transfection, cytoplas-
mic extracts from equal number of cells were
prepared, and the amount of DNA–histone
complexes was measured by the Cell Death
Elisa Assay. Every vector was transfected
into triplicate plates. The results (mean 6
standard error) are expressed as fold increase
in apoptosis (as measured by OD at 405 nm)
compared with cells transfected with vector
control.
Figure 2. Expression of OCI-5/
GPC3 in transiently trans-
fected MCF-7 cells. Equal
numbers of cells were trans-
fected with the indicated
HA-tagged OCI-5/GPC3 ex-
pression vectors. 48 h later
cells were lysed, and OCI-5/
GPC3 was immunoprecipi-
tated with an anti-HA
12CA5 antibody. The immu-
noprecipitates were then an-
alyzed by Western blot with
the same antibody. Lane a, untransfected controls; lane b, OCI-5/
GPC3; lane c, OCI-5/GPC3 DGAG; lane d, DOCI-5/GPC3. The
bracket indicates glycanated OCI-5/GPC3, the arrow the core
protein, and the arrowhead a cleaved fragment of the core pro-
tein. Numbers on the left represent molecular mass markers ex-
pressed in kD.
Figure 3. Western blot anal-
ysis of MCF-7 cells express-
ing inducible OCI-5/GPC3.
(Top) OCI-5/GPC3. Bracket,
glycanated OCI-5/GPC3; ar-
row, core protein; arrow-
head, cleavage product of
core protein. (Bottom)
PARP. The arrow indicates
the cleavage product of
PARP. Numbers on the left
represent molecular mass
markers expressed in kD. 
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tween OCI-5/GPC3–positive and –negative clones can be
observed. Indeed, after 2 d in serum-free conditions, a sig-
nificant proportion of cells in the OCI-5/GPC3–expressing
clones rounded up and detached. In control clones, on the
other hand, the number of floating cells was much lower
(Fig. 8). When the floating cells were stained with acridine
orange, they showed the typical pattern of apoptotic cells
with condensed and fragmented nuclei (data not shown).
This result indicates that the inhibitory activity of OCI-5/
GPC3 on II14 cells in the colony forming assay is, at least
in part, due to OCI-5/GPC3–induced apoptosis. The OCI-5/
GPC3–expressing clones that survive probably express
levels of the glypican that are insufficient to induce apop-
tosis in the presence of serum in subconfluent cultures but
are enough to do so in serum-free conditions.
 
Role of the GPI Anchor and the
Glycosaminoglycan Chains in the Apoptosis-inducing 
Activity of OCI-5/GPC3
 
Since glypicans can be secreted into the medium (David
et al., 1990; Watanabe et al., 1995), it was important to in-
vestigate whether the apoptotic activity of OCI-5/GPC3
requires the anchorage of this glypican to the cell mem-
brane. A deletion mutant was then generated by removing
the last 25 amino acids of OCI-5/GPC3. This fragment in-
cludes the sequences required for the addition of the GPI
tail, but not the consensus sequences required for the at-
tachment of the GAG chains (Filmus et al., 1988). To ver-
ify that this mutated glypican (
 
D
 
OCI-5/GPC3) was re-
leased into the medium, COS-1 cells were transiently
transfected with wild-type and mutant OCI-5/GPC3. Fig. 9
shows that, whereas most of the wild-type glycanated
OCI-5/GPC3 is found in the cell lysate, the mutant is pre-
dominantly present in the medium. The small amount of
mutant OCI-5/GPC3 that can be seen in the cell lysate is
probably peripheral and bound to the cell surface by elec-
trostatic interactions. It has already been shown that a sig-
nificant proportion of GPC1 remains bound to the cell sur-
face after cleavage of the GPI tail (Carey and Evans, 1989;
Bonneh-Barkay et al., 1997). It is also possible that we are
detecting OCI-5/GPC3 that is in transit from the Golgi ap-
paratus to the cell surface. When 
 
D
 
OCI-5/GPC3 was trans-
fected into II14 and MCF-7 cells, the number of geneticin-
surviving colonies was similar to the number observed
with the vector control (Table I). This result clearly indi-
cates that the inhibitory activity of OCI-5/GPC3 in the col-
ony forming efficiency assay requires its anchorage to the
cell surface. Several II14 clones transfected with the mu-
tant OCI-5/GPC3 were pooled and analyzed by Western
blot. As expected, most of the OCI-5/GPC3 was found in
the supernatant (data not shown). The requirement of the
Figure 4. Effect of inducible OCI-5/GPC3 expression on MCF-7
cells. Cells were incubated in regular medium with (b and d) and
without (a and c) 5 mM CdCl2 for 4 d and photographed. (a and
b) MCF-7 cells. (c and d) MT3 cells.
Figure 5. Cell Death Elisa
Assay of MCF-7 cells ex-
pressing inducible OCI-5/
GPC3. (a) MCF-7 cells, (b)
MCF-7 cells 1 5 mM Cd21,
(c) MT3 cells, (d) MT3 1 5
mM Cd21. Every cell line was
tested in triplicate plates.
The results (mean 6 stan-
dard error) are expressed as
fold increase in apoptosis (as
measured by OD at 405 nm)
compared with noninduced
MCF-7 cells.
Figure 6. Western blot anal-
ysis of OCI-5/GPC3 expres-
sion in transfected II14 cells.
Lane  a, parental II14 cells;
lanes b–d, clones transfected
with OCI-5/GPC3. Bracket,
glycanated OCI-5/GPC3; ar-
row, core protein; arrow-
head, cleavage product of
core protein. Numbers on the
left represent molecular mass
markers.The Journal of Cell Biology, Volume 141, 1998 1412
GPI tail for the apoptosis-inducing activity of OCI-5/
GPC3 was confirmed by transient expression assays in
MCF-7 cells. As shown in Fig. 1, the percentage of OCI-5/
GPC3–transfected cells that undergo apoptosis is similar
to that obtained by transfection with vector control, de-
spite the fact that the transfected glypican is highly ex-
pressed in the transfected cells (Fig. 2).
It has been clearly established that the GAG chains play
an important role in the interactions of cell surface pro-
teoglycans with growth factors and cell adhesion mole-
cules (Wight et al., 1992; Rapraeger et al., 1994; Salmivirta
et al., 1996). In the particular case of glypicans, however, it
has been proposed that the core proteins have functions in
addition to acting as anchors for GAG chains. This hy-
pothesis is based on the observation that the sequence of
glypicans is highly conserved during evolution and that the
GAG insertion sites are all located close to the COOH
terminus (Stipp et al., 1994; Saunders et al., 1997). It was
decided, therefore, to investigate whether the GAG chains
of OCI-5/GPC3 are required for its apoptosis-inducing ac-
tivity. To do this, the serines at the two potential GAG at-
tachment sites were converted into alanines. To verify that
these mutations inhibited the addition of GAG chains, the
mutated glypicans were transiently transfected into [35S]sul-
fate-labeled COS-1 cells and analyzed by immunoprecipi-
tation and autoradiography. Fig. 10 shows that, as expected,
cells transfected with OCI-5/GPC3 in which both serines
have been mutated do not show any signal after immuno-
precipitation. The glypicans with only one serine mutated,
on the other hand, show bands whose mobility indicate
that they correspond to proteoglycans that are smaller than
the wild-type OCI-5/GPC3.
The GAG-deficient mutant was then tested for its apop-
tosis-inducing ability. Both the colony-forming efficiency
assay and the transient expression assay showed that the
DGAG chains are not required for the OCI-5/GPC3 apop-
tosis-inducing activity (Table I and Fig. 1). In the case of
MCF-7 cells, the efficiency of the apoptosis-inducing activ-
ity of DOCI-5/GPC3 seems to be lower than wild type. We
have assessed the level of expression of OCI-5/GPC3
DGAG by Western blot analysis of transiently transfected
Figure 7. Western blot analysis of endogenous OCI-5/GPC3 ex-
pression. (A) Normal NRM2 rat mesothelial cells (lane a) and
II14 mesothelioma cells (lane b) were lysed, and OCI-5 was im-
munoprecipitated with 10 mg/ml of affinity-purified anti–OCI-5
polyclonal antibody. The immunoprecipitated material was ana-
lyzed by Western blot using the same antibody (1 mg/ml). The ar-
row indicates the OCI-5/GPC3 core protein, and the arrowhead
indicates the Ig band. The glycanated form of OCI-5 could not be
detected in the conditions used here. (B) HepG2 hepatoma cells
(lane a) and COS-1 fibroblasts (lane b) were lysed, and expres-
sion of OCI-5/GPC3 was analyzed by Western blot with 1 mg/ml
of affinity-purified anti-GPC3 polyclonal antibody. The arrow in-
dicates the GPC3 core protein, and the bracket indicates the gly-
canated GPC3.
Figure 8. Effect of OCI-5/GPC3 expression in II14 cells. Cells
were incubated in serum-free conditions for 48 h, and the number
of floating cells was counted. Results are the mean value 6 stan-
dard error of triplicates. (a) II14 cells. (b and c) Clones trans-
fected with vector alone. (d–f) Clones expressing OCI-5/GPC3.
Figure 9. Western blot anal-
ysis of GPI domain-deletion
mutant. cell, immunoprecipi-
tated cell lysates: (lane a)
Cells transfected with vector
alone; (lane b) cells trans-
fected with wild-type OCI-5/
GPC3; (lane c) cells trans-
fected with DOCI-5/GPC3.
sup, conditioned media: (lane
a) Cells transfected with
wild-type OCI-5/GPC3; (lane
b) cells transfected with
DOCI-5/GPC3. Numbers on
the middle represent molecu-
lar mass markers.
Figure 10. Analysis of GAG-
deleted mutants by immuno-
precipitation of [35S]sulfate-
labeled cells. Cells were
transfected with: lane a, vec-
tor alone; lane b, wild-type
OCI-5/GPC3; lane c, serine
494 to alanine mutant; lane d,
serine 508 to alanine mutant;
lane e, serines 494 and 508 to
alanines mutant. Numbers on
the left represent molecular
mass markers.Gonzalez et al. Glypican-3 Induces Apoptosis in a Cell Line–specific Manner 1413
cells (Fig. 2). This type of analysis, however, is not quanti-
tative enough to allow us to establish whether the lower
apoptosis-inducing activity of the mutant is due to lower
levels of expression or to the fact that GAG chains of
OCI-5/GPC3 play a role in the induction of cell death in
MCF-7 cells.
Insulin-like Growth Factors Can Rescue MCF-7 Cells 
from GPC3-induced Apoptosis
SGBS shares many clinical features with the Beckwith-
Wiedemann Syndrome (Verloes et al., 1995; Weksberg
et al., 1996). This disorder is thought to be in most cases
the result of the overexpression of insulin-like growth fac-
tor (IGF-2), a growth factor that can also act as a survival
factor (Harrington et al., 1994). It has been proposed,
therefore, that OCI-5/GPC3 is involved in the downregu-
lation of IGF-2 activity (Hughes-Benzie et al., 1996; Pilia
et al., 1996). Although our studies have indicated that
OCI-5/GPC3 does not interact directly with IGF-2 (Song
et al., 1997), it is possible that OCI-5/GPC3 regulates IGF-2
activity by interacting with other molecules involved in
IGF-2 signaling. We decided, therefore, to test whether
this factor can rescue MCF-7 cells from OCI-5/GPC3–
induced apoptosis. Thus, physiological concentrations of
IGF-2 were added to the MT3 clone in which OCI-5/
GPC3 expression had been induced for 2 d, and the degree
of apoptosis was quantitated 2 d later by the Cell Death
Elisa Assay. It can be seen in Fig. 11 that IGF-2 was able
to completely rescue the MT3 cells from cell death. In par-
allel, we also tried to rescue the MT3 cells with IGF-1,
FGF-1, and EGF. These factors are also known to be able
to act as survival factors in certain cell types (Guillonneau
et al., 1997; Hague et al., 1997; Rodeck et al., 1997). Only
IGF-1 was able to inhibit OCI-5/GPC3–induced apoptosis
of MT3 cells (Fig. 11).
Discussion
We have shown here that OCI-5/GPC3, a heparan sulfate
proteoglycan that is bound to the cell surface through a
GPI tail, can induce apoptosis in the II14 rat mesothe-
lioma cell line and in the MCF-7 breast cancer cell line.
This conclusion is based on results obtained with three dif-
ferent experimental approaches: colony forming efficiency
assays, transient expression, and the generation of cell
lines with inducible and constitutive expression of OCI-5/
GPC3. With regard to the last approach, it is important to
note that we have recently generated MCF-7 clones in
which the expression of OCI-5/GPC3 is regulated by the
tetracycline-inducible system (Gossen et al., 1993). In
these clones we have also verified that OCI-5/GPC3 in-
duces apoptosis (data not shown).
To our knowledge, this is the first report demonstrating
that a cell surface heparan sulfate proteoglycan can induce
programmed cell death. Some GPI-anchored proteins, on
the other hand, have already been shown to be involved in
apoptosis (Brodsky et al., 1997). OCI-5/GPC3 has been
implicated as the gene whose loss of function mutations is
responsible for the generation of SGBS (Hughes-Benzie
et al., 1996; Pilia et al., 1996). Interestingly, some of the
features of SGBS, such as syndactyly, and the presence of
supernumerary nipples and coccygeal bony appendage,
could be the consequence of defective apoptosis during
development (Hughes-Benzie et al., 1996; Jacobson et al.,
1997). The results presented here, therefore, provide im-
portant clues regarding the mechanism that, at least in part,
is involved in the generation of SGBS. Another important
finding of this work is that the apoptotic-inducing activity
of OCI-5/GPC3 is cell line specific, since we failed to observe
such activity in NIH 3T3 fibroblasts and HT-29 colorectal
tumor cells. This is also consistent with the phenotype of
SGBS patients since only certain organs at particular
stages of development are affected in this syndrome.
One of the main phenotypic characteristics of SGBS pa-
tients is overgrowth. Although we have shown here that
OCI-5/GPC3 induces apoptosis in II14 and MCF-7 cells,
we do not exclude the possibility that in other cell types
this glypican could induce growth inhibition. A typical ex-
ample of this is p53, a tumor suppressor that, depending
on the cell type, can induce growth arrest or apoptosis
(Polyak et al., 1996).
As discussed above, the similarities between SGBS and
Beckwith-Wiedemann Syndrome strongly suggest that
OCI-5/GPC3 is a negative regulator of IGF-2 signaling. In
addition, it has been recently reported that transgenic
mice that express very high levels of IGF-2 display several
features that resemble SGBS (Eggenschwiler et al., 1997).
Thus, our finding that IGFs can rescue MCF-7 cells from
OCI-5/GPC3–induced apoptosis is consistent with the idea
that, in some way, the signaling pathway that IGF-2 uses
Figure 11. Effect of growth factors on OCI-5/GPC-3–induced apop-
tosis of MCF-7 cells. OCI-5/GPC3 expression was induced by
adding 5 mM Cd21 to the MT3 cells. 2 d later, 50 ng/ml of IGF-1,
IGF-2, EGF, and FGF-1 were added, and cells were incubated
for two more days in the presence of the inducer and the added
factors. Every factor was tested in triplicate plates. The results
(mean 6 standard error) are expressed as fold increase in apop-
tosis (as measured by OD at 405 nm) compared with noninduced
MT-3 cells (Cont.).The Journal of Cell Biology, Volume 141, 1998 1414
while acting as a survival factor intersects with the path-
way used by OCI-5/GPC3 for its apoptotic-inducing activ-
ity. In this respect, this study provides two important clues
regarding the molecular interactions that could explain the
mechanism by which OCI-5/GPC3 is able to induce apop-
tosis. First, we have shown that OCI-5/GPC3 has to be an-
chored to the cell membrane. This suggests that OCI-5/
GPC3 activity requires interaction with molecule(s) lo-
cated in the cell membrane. Second, we have found that
the GAG chains are not required for the apoptosis-induc-
ing activity. Our second finding is particularly important,
since we have previously reported that OCI-5/GPC3, like
other heparan sulfate proteoglycans, has the ability to in-
teract directly with basic fibroblast growth factor through
its GAG chains (Song et al., 1997). The fact that the GAG
chains are not required suggests that, at least for the induc-
tion of apoptosis in these cells, the interaction with basic
fibroblast growth factor (or any other heparin-binding
growth factor) is not important. Our finding demonstrates,
on the other hand, that as suspected, the protein core of
OCI-5/GPC3 has functions that do not depend on the GAG
chains. Moreover, given the high abundance of the nongly-
canated form of (endogenously or exogenously trans-
fected) OCI-5/GPC3 in several cell types, one possibility
to be explored is that only the nonglycanated form of OCI-5/
GPC3 is responsible for this apoptosis-inducing activity.
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